Introduction
Poxafil Tablet (Delayed Release) 100 mg is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Uses
Poxafil Tablet (Delayed Release) 100 mg is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with prolonged neutropenia from chemotherapy. Also for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole. Poxafil Tablet (Delayed Release) 100 mg is used as an alternative treatment for invasive aspergillosis, Fusarium infections, and zygomycosis in patients who are intolerant of, or whose disease is refractory to, other antifungals.
Associated Conditions
Pharmacodynamics
Poxafil Tablet (Delayed Release) 100 mg is an antifungal agent structurally related to itraconazole. It is a drug derived from itraconzaole through the replacement of the chlorine substituents with flourine in the phenyl ring, as well as hydroxylation of the triazolone side chain. These modifications enhance the potency and spectrum of activity of the drug. Poxafil Tablet (Delayed Release) 100 mg can be either fungicial or fungistatic in action.
Mechanism of Action
As a triazole antifungal agent, posaconazole exerts its antifungal activity through blockage of the cytochrome P-450 dependent enzyme, sterol 14α-demethylase, in fungi by binding to the heme cofactor located on the enzyme. This leads to the inhibition of the synthesis of ergosterol, a key component of the fungal cell membrane, and accumulation of methylated sterol precursors. This results in inhibition of fungal cell growth and ultimately, cell death.
Absorption
Poxafil Tablet (Delayed Release) 100 mg is absorbed with a median Tmax of approximately 3 to 5 hours.
Volume of Distribution
- 1774 L
Protein Binding
Poxafil Tablet (Delayed Release) 100 mg is highly protein bound (>98%), predominantly to albumin.
Route of Elimination
The excreted metabolites in urine and feces account for ~17% of the administered radiolabeled dose.
Half Life
Poxafil Tablet (Delayed Release) 100 mg is eliminated with a mean half-life (t½) of 35 hours (range 20 to 66 hours).
Clearance
- 32 L/hr
- 51 L/hr [Single-Dose Suspension Administration of 200 mg, fasted]
- 21 L/hr [Single-Dose Suspension Administration of 200 mg, nonfat meal]
- 14 L/hr [Single-Dose Suspension Administration of 200 mg, high fat meal]
- 91 L/hr [Single-Dose Suspension Administration of 400 mg, fasted]
- 43 L/hr [Single-Dose Suspension Administration of 400 mg with liquid nutritional supplement (14 g fat)]
Toxicity
During the clinical trials, some patients received posaconazole up to 1600 mg/day with no adverse events noted that were different from the lower doses. In addition, accidental overdose was noted in one patient who took 1200 mg BID for 3 days. No related adverse events were noted by the investigator.
Food Interactions
- Take with food. Poxafil Tablet (Delayed Release) 100 mg suspension can also be taken with a nutritional supplement drink or carbonated beverage if a full meal cannot be consumed.
Dosage
Loading Dose: 300 mg (3 Tablets) twice a day on the first day.
Maintenance Dose: 300 mg (3 Tablets) once a day from the second day.
Duration of therapy should be based on the severity of the underlying disease, recovery from immunosuppression and clinical response.